UFikelelo olutsha kwiQonga lokuJonga uMhlaza

A BAMBA isiKhululo sasimahla 5 | eTurboNews | eTN
IAvatar kaLinda Hohnholz
Ibhalwe ngu Linda Hohnholz

I-Invitae namhlanje ibhengeze ukufikelela okugcweleyo kwiqonga layo le-Personalized Cancer Monitoring (PCMTM) ukunceda ukufumanisa isifo esincinci okanye se-molecular residual (MRD) kwizigulana ezinamathumba aqinileyo. I-Invit PCM isebenzisa iseti yenoveli yovavanyo olulolwakho olusekelwe kwithumba lesigulana lokubona i-tumor ejikelezayo ye-DNA (ctDNA) egazini, inika isakhono sokwenza ulwahlulo lomngcipheko, uvavanyo lokuphendula kunyango kunye nobhaqo lokuphinda umhlaza, ngokusekelwe kwizifundo zamva nje.

"I-stratification yomngcipheko wokubuyisela iyimfuneko yeklinikhi kwizigulane ezininzi ezifumana unyango lwe-tumor eqinile kwaye isetyenziswe kakuhle ngezixhobo ze-molecular ezihlaziyiweyo ukuze zincedise kwaye ziphuculwe kumgangatho weendlela zokunyamekela ukufunyanwa kwakhona," kusho uRobert Nussbaum, MD, oyintloko. igosa lezonyango, Mema. "Iqonga le-PCM lincedisa iindlela zokubeka iliso zangoku, kwaye linamandla okufumanisa ukusebenza konyango lomhlaza kwangaphambili kunezo ndlela zezigulane ezininzi, okuvumela oogqirha ukuba bafumane ithuba lokucokisa ukhetho lonyango."

Kwiminyaka emininzi edlulileyo, uphando oluvela kwi-Invitae kunye noluntu olukhulu lwezenzululwazi, kubandakanywa uphando lwe-TRACERx olukhokelwa nguNjingalwazi uCharles Swanton kwiFrancis Crick Institute kunye neYunivesithi yaseLondon (UCL), kunye nenkxaso-mali yeCancer Research UK, ibonise ukuba ukubeka iliso kwe-MRD ngokuthembekileyo chonga abaguli abanomhlaza wemiphunga abasengozini enkulu yokuphinda babuyele kunyango, bafumanise ukuvela kwakhona emva kotyando rhoqo ngaphambi kokwenza utyando oluqhelekileyo, kuvavanya impendulo yonyango, kwaye kunokwenzeka ukuba ube ngumntu obambeleyo kwiziphelo zolingo lweklinikhi. Ngobu buchule, uhlolo lwe-MRD luthembisa ukwenza mfutshane ulingo lwezonyango kunye nokukhawulezisa uphuhliso lwamachiza amatsha anokusindisa ubomi. I-Invitae PCM yi-pan-cancer, i-tumor-informed liquid biopsy assay, iphuhliswe ngokubambisana ne-TRACERx consortium, esebenzisa isizukulwana esilandelayo sokulandelelana (NGS) ukuhlalutya i-ctDNA kwi-plasma yesigulana.

"I-MRD yinto ebalulekileyo ye-biomarker kwixesha le-adjuvant kunye ne-surveillance," watsho uNjingalwazi uCharles Swanton, i-MBPhD, i-FRCP, i-FMedSci, i-FRS, i-FAACR, kwi-Francis Crick Institute kunye ne-UCL Cancer Institute kunye ne-Chief Clinician yeCancer Research UK. "Njengoko sibonile kuphononongo lwe-TRACERx, i-PCM ibonelela ngolwazi lwe-prognostic, inokunceda kwiimeko ze-radiographic ambiguity, kwaye ibonisa ubuntununtunu obuphezulu beklinikhi kunye neenkcukacha."

Uvavanyo lwe-biopsy yolwelo lukhona ekukhetheni unyango, kodwa ukuchonga i-MRD kwibakala lakwangoko kuneendlela eziqhelekileyo phambi kokuba izigulana zibuyele ekliniki, itekhnoloji kufuneka ibe novakalelo ngokwaneleyo ukuze ibone i-ctDNA kumanqanaba aphantsi kakhulu. Ukongeza, uvavanyo lwe-MRD oluneenkcukacha eziphezulu luyafuneka ukunciphisa ukubakho kweziphumo ezingezizo ezichanekileyo. Uvavanyo lwe-PCM lusebenzisa itekhnoloji ephucukileyo ukufika kumanqanaba aphezulu obuntununtunu kunye nokucaciswa, ukufumanisa i-tumor DNA kumanqanaba aphantsi kakhulu okugxilwa kwigazi le-peripheral. Izifundo zokuqinisekisa zibonisa ngaphezulu kwe-99.9% ubuntununtunu ekufumaneni i-ctDNA kwi-0.008% eyahlukileyo rhoqo.

"Siyavuya malunga nokufumaneka kwe-PCM kwihlabathi jikelele, njengoko le yindawo eguquguqukayo apho sityale imali kulo nyaka uphelileyo kwaye sikholelwa ukuba sinakho ukunika izigulane ulwazi olufunekayo ukuze ziqonde umngcipheko wokuphindaphinda ukulwa nokubetha isifo," kusho uSean. George, Ph.D., umseki kunye ne-CEO ye-Invitae.

Uvavanyo ngalunye lwenziwe ngokwesiko ukufumanisa utyikityo lwethumba olulodwa lwesigulane, luvumela iziphumo zobuqu ukukhokela izigqibo zonyango. Isimemo PCM ifuna zombini igazi kunye nethumba iisampulu ithishu ukusuka isigulana ukuqhuba ithumba-eqhelekileyo lonke exome ulandelelwano (WES). Ngokusekelwe kwiziphumo, i-algorithm yobunikazi ye-Invitae ikhetha i-18-50 ye-tumor-specific variants ukuba ibandakanye kwiphaneli ye-ctDNA yesiko yesiko. Olu luhlu lwezahlukaniso luvumela ulungelelwaniso lwe-MRD ebuthathaka kakhulu kunye nobhaqo oluthile lwe-MRD kwi-cancer enemithwalo ephantsi okanye ephezulu yokuguqulwa.

Ukuba isiphumo se-MRD-positive sifunyenwe nakweyiphi na indawo kuhambo lwesigulana somhlaza, ugqirha kunye nesigulane banokuxoxa ngeziphumo zesiphumo kunye nonyango olufanelekileyo okanye ukhetho lwezonyango. “Olu lwazi lwemolekyuli luchaphazela abaguli abanomhlaza kulo lonke uhambo lwabo lomhlaza, nto leyo eyenza ukuba ibe yeyona nto iphambili kwi-oncology echanekileyo,” utshilo uGeorge.

I-Invitae ikhulisa iphothifoliyo yophando kwihlabathi jikelele ukuqhubeka nokuqokelela idatha kwi-PCM eluncedo lwezonyango kunye nezifundo ezikhokelwa yi-MRD. I-Invitae ilindele upapasho oluninzi kulo nyaka kwizifundo zayo ze-PCM kwimiphunga, ibele, intloko kunye nentamo, kunye ne-GI tumors kunye nezifundo ezininzi ezilindelekileyo eziqalayo kwisiqingatha sokuqala sonyaka. Ezi zifundo zilindelekileyo ziquka uphando lwe-pan-tumor (MARIA) kunye nezifundo ezininzi kwi-breast kunye ne-GI yomhlaza, kuquka i-ARTEMIS, uphononongo oluvavanya i-PCM ye-Invitae enikezela ngokukodwa kwizigulane ezinomhlaza we-pancreatic. Uphononongo luya kuqhutywa ngokubambisana neziko eliphezulu elikufutshane neTokyo, iNational Cancer Centre Hospital East, Kashiwa, Chiba, Japan. Ukuqokelelwa kwesampulu kuya kuqala kwi-Q2 2022.

Malunga nombhali

IAvatar kaLinda Hohnholz

Linda Hohnholz

Umhleli oyintloko we eTurboNews esekwe kwi-eTN HQ.

Bhlisa
Yaziswe ngawo
guest
0 izimvo
Inline feedbacks
Jonga zonke izimvo
0
Ndingazithanda iingcinga zakho, nceda uphawule.x
Yabelana ku...